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Introduction. Preclinical, clinical and population studies have provided robust 
evidence for an important role for the insulin-like growth factor (IGF) system in 
the development of prostate cancer. 
 
Areas Covered. An overview of the IGF system is provided. The evidence 
implicating the IGF system in the development of prostate cancer is summarised. 
The compelling evidence culminated in a number of clinical trials of agents 
targeting the system; the reasons for the failure of these trials are discussed.  
 
Expert Commentary. Clinical trials of agents targeting the IGF system in 
prostate cancer were terminated due to limited objective clinical responses  and 
are unlikely to be resumed unless a convincing predictive biomarker is identified 
that would enable the selection of likely responders. The aging population and 
increased screening will lead to greater diagnosis of prostate cancer. Although 
the vast majority will be indolent disease, the epidemics of obesity and diabetes 
will increase the proportion that progress to clinical disease. The increased 
population of worried men will result in more trials aimed to reduce the risk of 
disease progression; actual clinical endpoints will be challenging and the IGFs 
remain the best intermediate biomarkers to indicate a response that could alter 
the course of disease.  
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Prostate cancer is one of the major epithelial cancers, having the highest 
incidence for men in 114 countries globally and the leading cause of cancer death 
in men in 56 countries [1]. Since the introduction of screening by the 
measurement of prostate specific antigen (PSA) in the circulation in the 1990’s 
incidence rates rose rapidly in countries where such screening was adopted 
generally, such as Australia and the USA, and then declined as the prevalence of 
undetected cases was diminished. In other countries where such screening has 
been adopted more gradually, such as many European countries, the changes in 
incidence have been less marked. In countries where screening remains rare the 
incidence has been gradually rising [2]. Mortality from prostate cancer has been 
decreasing in many developed countries and this decrease has been attributed to 
early detection due to PSA screening and improved treatments [3]. The 
interpretation of such statistics is however far from straightforward and many 
confounding issues need to be considered. As the strongest risk factor for 
prostate cancer is age and the number of men living into old age is increasing in 
many populations, this clearly will increase the incidence of such cancers. In 
relation to incidence rate, this is largely affected by the method of detection and 
it is now widely recognised that screening with PSA results in considerable over-
diagnosis. Over-diagnosis with screening results in many men being treated who 
would not have presented with symptoms during their lifespan and as treatment 
is commonly associated with complications, such as incontinence and impotence, 
this can result in considerable reduction in quality of life [4]. It has been 
estimated that screening results in 27 men being treated in order to save the life 
of one man [5]. The enthusiasm for screening in the USA led many to attribute 
the subsequent fall in mortality to early detection; however similar falls in 
mortality over the same time-span in countries without screening suggest this 
may be more complicated [5,6]. If mortality is presented as survival after 
diagnosis, then as adoption of screening results in a large increase in detected 
incident cases, this will misleadingly give the impression that there had been a 
major improvement in survival. But as many of those detected with indolent 
cancers would have not presented with symptoms and would not die from these 
cancers regardless of treatment, then there can be an apparent improvement in 
survival even if there were no actual change in mortality due to changes in 
treatment. The confusion over issues in relation to screening, over-diagnosis and 
over-treatment indicate that the critical challenge in relation to prostate cancer 
will be to identify men who will develop clinically significant disease and 
distinguish these from men with insignificant disease that will pose little or no 
danger to their life [7]. The high prevalence of indolent, clinically insignificant, 
prostate cancers is entirely consistent with the findings from numerous autopsy 
studies that have identified cancer in the prostates of men who died from 
unrelated causes [8,9]. The occurrence of indolent prostate cancers detected at 
autopsy has consistently been found even in men in their 20s, at an age when 
clinical disease is extremely rare, and to increase with age with up to 80% 
prevalence in men in their 80’s [10]. The high prevalence has been found in all 
populations and appears unrelated to incidence of clinical disease. The 
prevalence of cancer found in prostates at autopsy were similar in black and 
white men in the USA despite a higher incidence of clinical disease and 2-3-fold 
higher prostate cancer mortality in the black men [11,12]. The frequency of 
latent carcinomas in prostates of Japanese men found at autopsy were also 
similar to that of white men in the USA despite a much lower rate of incident 
disease and mortality in Japan [13]. Similar rates of prostate cancer at autopsy 
were also found in a comparison of Caucasian men from Russia and men from 
Japan [14]. The similarity in prevalence of prostate cancer detected at autopsy 
between different geographical regions is in marked contrast to the incidence of 
overall and age-specific clinical disease which show substantial variations 
regardless of the level of PSA-testing, with the lowest rates consistently seen in 
Asia [2].  Indeed, studies of migrants between different countries indicate that 
environment has little impact on the prevalence of latent cancers but a large 
effect on the rates of clinical disease. For example, Japanese that have migrated 
to Hawaii have a higher prostate cancer incidence and mortality than indigenous 
Japanese although the rates of latent carcinoma detected at autopsy were similar 
between the two groups [15].  
A number of inferences can be made from these various observations: indolent 
occult cancers appear in the prostate as men age, such that they are common in 
most elderly men; there may be a long latency period between initiation and 
appearance of clinical disease and progression to clinical disease may depend on 
environmental or lifestyle factors. The high prevalence of occult prostate cancers 
and the potential effect of lifestyle on their progression to clinical disease is 
consistent with the recent mounting evidence indicating the ubiquitous 
accumulation of oncogenic mutations with age in rapidly turning-over epithelial 
tissues and the impact of lifestyle [16]. This means that in addition to the 
challenge of identifying the clinically relevant cancers there is also an 
opportunity: with many men diagnosed with sub-clinical cancers, these men 
present as a large cohort for the development of interventions to prevent these 
men with cancer from progressing to life-threatening disease. Of the modifiable 
lifestyle factors, a Western lifestyle and diet has been implicated in the 
progression of prostate cancer and considered as a factor in the geographical 
variations observed. Lifestyle factors including excess energy intake, physical 
inactivity, obesity and insulin resistance have all been associated with prostate 
cancer development and poor outcomes [17]. Indeed, a Western-type diet fed to 
mice increased the growth, histological grade and metastasis of prostate cancers 
in mice [18]. The realisation that lifestyle, and especially diet, may play an 
important role in prostate cancer development has focused interest on 
nutritional regulators. The insulin/insulin-like growth factor (IGF) system has 
been throughout evolution the most fundamental regulator of tissue growth and 
development according to nutritional status and we will review recent evidence 
of the involvement of this system in prostate cancer.   
1.1. The insulin/IGF system. 
Insulin and its precursor, proinsulin, are secreted from specialist endocrine -
cells in the pancreas in order to regulate the distribution and utilisation of 
nutrients, especially glucose, in response to ingested food arriving in the gut. 
Early in evolution gene duplication events gave rise to two further peptides, IGF-
I and IGF-II, that share around 50% homology with proinsulin; indeed the IGF-II 
gene is still found on chromosome 11 adjacent to the insulin gene [19]. The IGF-
II gene has however evolved into an extremely complex genetic loci compared to 
that of insulin. The human IGF-II gene is driven by 5 promoters and controlled by 
a downstream imprinting control region between the IGF-II gene and that of H19 
and which via differential methylation controls both genes [19]. In some tissues 
and at certain stages of development this ensures that only the paternal allele of 
IGF-II and the maternal allele of H19 are expressed. The regulation of IGF-II is 
further complicated by the presence of three IGF-II mRNA binding proteins  
(IMP1, IMP2, IMP3) that control the stability and translation of IGF-II mRNA and 
glucose regulated protein 94 (GRP94) a chaperone that ensures the correct 
folding of IGF-II peptide [19]. The IMPs and GRP94 are not specific exclusively 
for IGF-II but they are important components of the system and GRP94 appears 
essential for the secretion of IGF-II. In addition to IGF-II, the loci also gives rise to 
at least three long non-coding RNA (lnc-RNA), IGF-II-antisense, H19 and its 
antisense transcript, H91 and at least four micro-RNAs [19]. Two additional 
regulatory peptides are also derived from the locus, preptin and H19 opposite 
tumor suppressor (HOTS) [19].  In contrast to insulin, the IGFs are secreted from 
most cells throughout the body and have additional, broader regulatory 
functions [20]. Indeed, the IGFs are powerful mitogens and strong survival 
factors for most cell types [20]. The IGFs, however, also retain their insulin-like 
metabolic activity; indeed IGF-II was originally identified in bioassays as non-
suppressible insulin-like activity responsible for more than 90% of the glucose-
uptake stimulating activity found in serum [19].  
The IGFs activate cell surface transmembrane tyrosine kinase receptors (IGF-IR) 
that are also very homologous to the insulin receptor (IR) and again these 
presumably arose from an early gene duplication event (figure 1). These 
receptors are expressed and cleaved into an extracellular -subunit that binds 
insulin/IGFs outside the cells and a transmembrane -subunit that contains the 
tyrosine kinase catalytic site within the cell. These two subunits then dimerise 
further to form a heterotetrameric complete receptor. The IGF-IR appears to be 
the primary IGF receptor as it binds both IGF-I and IGF-II and has a relatively low 
affinity for insulin. In contrast the insulin receptor is more complicated as it 
exists in two isoforms, due to alternative splicing of the -subunit that alters the 
ligand-binding domain resulting in IR-A and IR-B. The classical insulin receptor 
appears to be IR-B, which predominantly binds to insulin and has a much lower 
affinity for IGFs. In contrast IR-A has an affinity for IGF-II that is comparable to 
that of insulin and a consideration of the relative abundance of IGF-II in the body, 
compared to the low concentrations of insulin, indicates that insulin would only 
activate IR-A in the immediate post-prandial state and for the majority of the 
time IR-A would act as an IGF-II receptor [21]. Although IGF-II binds to IR-A with 
a similar affinity to insulin, there is evidence that IGF-II results in a prolonged 
activation of ERK1/2 compared to insulin and this may contribute to a more 
mitogenic and less metabolic response [22,23]. The --dimers of the IR and IGF-
IR are so similar that they hetero-dimerise to form hybrid receptors, both IR-
A/IGF-IR hybrids and IR-B/IGF-IR hybrids, depending on the relative expression 
of each receptor in any particular cell. These hybrid receptors appear to 
predominantly act as IGF-I receptors [24], but their pathophysiology is still far 
from understood. 
 
Intracellular signaling is initiated when insulin/IGFs bind to the -subunit of 
these receptors inducing a conformational change that results in activation of the 
tyrosine kinase activity contained within the intracellular -subunit. This then 
results in autophosphorylation of multiple intracellular sites that provide 
docking sites for the recruitment of a variety of adaptor proteins, including the 
insulin receptor substrates (IRS-1 to−4), Shc and receptor for activated C kinase 
1 (RACK1). This then facilitates the assembly of signaling complexes that activate 
networks of signaling pathways. The two best characterized of these are 
the PI3K/Akt/mTOR/S6K and Grb2/SOS/Ras/Raf/MEK/ERK pathways [25]. The 
lipid kinase activity of PI3K, that recruits and activates Akt, is opposed by the 
lipid phosphatase PTEN (phosphatase and tensin homolog), a tumor suppressor 
gene, the expression of which is commonly suppressed in many cancers 
including prostate. 
 
There is also a very specific IGF-II receptor (IGF-IIR) that is both structurally and 
functionally completely different from the IR and IGF-IR and is a single large 
transmembrane protein [26,27]. The IGF-IIR binds IGF-II with extremely high 
affinity and has very little affinity for IGF-I or insulin. Binding of IGF-II to the IGF-
IIR is generally considered not to initiate any conventional intracellular signaling 
but results in internalization and targeting of IGF-II to the lysosomes for 
degradation. The IGF-IIR is therefore thought to act as a clearance receptor for 
IGF-II, tightly controlling the exposure of IGF-II to the other signaling receptors. 
In contrast to insulin, which is stored in large amounts in the pancreas, there are 
no intracellular stores of IGFs; however, a sophisticated system has evolved for 
maintaining extracellular stores of IGFs throughout the body due to their 
association with very specific high affinity binding proteins. There are 6 binding 
proteins (IGFBP-1 to −6) that bind to both IGF-I and IGF-II with high affinity but 
do not bind insulin. The IGFBPs are not related to the cell-surface receptors but 
they are structurally very closely related to each other although they have very 
distinct functional properties and are produced in different quantities and 
combinations in different tissues [28]. The primary effect of the IGFBPs is that 
they considerably slow the clearance of IGFs, enabling very high concentrations 
of IGFs to build-up. In the circulation when IGFs associate with IGFBP-3 and 
IGFBP-5, these binary complexes immediately bind to a further large 
glycoprotein, the acid labile subunit (ALS) that is present in excess. This ternary 
complex is then too large to cross capillaries and hence is retained in the 
circulation and further slows clearance. This enables the total IGF-I and IGF-II 
concentration in the circulation to accumulate to around 1,000 times higher 
concentration than that of insulin and while insulin levels fluctuate acutely in 
response to metabolic requirements, the circulating concentrations of the IGFs 
are very stable due to the very slow clearance of the IGF/IGFBP complexes [20]. 
Despite being expressed in most tissues, the majority of the IGFs present in the 
circulation originate from the liver, where the production of both IGF-I and 
IGFBP-3 are regulated by growth hormone (GH) but in addition they are also 
very dependent on nutritional status [29]. At the cellular level, both the IR and 
IGF-IR are optimally activated by just 1–2 nanomolar concentrations of IGFs or 
insulin; this indicates that there is a vast excess of IGFs in the body. The high, and 
very stable, concentrations of circulating IGFs therefore establish a large 
reservoir of metabolic regulators that is determined by the chronic nutritional 
status. The IGFs can be released from this reservoir in a controlled manner, 
primarily by specific proteases that act on the IGFBPs and lower their affinity. 
This shifts the equilibrium and enables the IGFs to dissociate and then to bind 
and activate cell surface receptors [30]. This has important implications for 
cancers such as that of the prostate; these cancers only become life threatening 
when they invade and spread to tissues outside of the prostate, a process that 
depends on the proteolytic degradation of the extracellular matrix (ECM) to 
enable invasion and angiogenesis. This proteolysis can then also act on IGFBPs to 
mobilize the large reservoirs of latent IGFs [28]. In addition to their role in 
modulating the availability and activity of the IGFs, many other actions, 
independent of binding to IGFs have been described for the IGFBPs [28]. Some of 
the best characterised of these IGF-independent actions, and of particular 
relevance to cancers, are the effects of both IGFBP-2 and IGFBP-3 on cell survival 
and DNA-repair [28,31,32]. One of the critical signaling pathways activated by 
the IGFs is the PI3K/Akt pathway and IGFBP-2 not only binds to the IGFs to 
modulate their activity but it also binds to integrin receptors and suppresses the 
activity of PTEN, the phosphatase that switches off the PI3K/Akt pathway [33]. 
In this way IGFBP-2 controls not only the ‘on’-switch but also the ‘off’-switch for 
controlling cell signaling. PTEN is a tumor suppressor gene which when reduced 
has important implications for prostate cancer prognosis [34,35] and IGFBP-2 
has been shown to be a novel suppressor of PTEN in prostate cancer cells [36].  
 
2. Evidence from population studies implicating IGFs in prostate cancer. 
Interest in aspects of lifestyle that could affect the development of prostate 
cancer led to epidemiological investigations of factors that could be measured in 
population studies and their association with prostate cancer incidence. A 
number of hormones were measured in blood samples that were collected from 
large population screens. Due to the potential for cancers to affect the levels of 
hormones; especially those affected by deteriorating metabolic status, it was 
always apparent that interpretation of retrospective cohort studies of men with 
prostate cancer could be confounded by reverse causality. Particular interest 
therefore focused on prospective epidemiology in which hormones could be 
measured in blood samples that were obtained from healthy men in studies with 
many years subsequent follow-up. This enabled the examination of which 
hormones affected the subsequent risk of the men developing prostate cancer. 
There is considerable inter-individual variation in the levels of most hormones 
within populations and therefore very large populations are required to show 
associations with disease. After initial reports from individual studies, 
collaborations were established to increase population size and enhance the 
power to show such associations. An international collaboration combining 18 
prospective studies that included 3,886 men who subsequently developed 
prostate cancer and 6,438 control men found that there was no association 
between the circulating levels of any sex steroid, including several androgens, 
and the subsequent risk of prostate cancer [37]. In contrast a similar exercise 
with 12 prospective studies including 3,700 men who subsequently developed 
prostate cancer and 5,200 control men found that the circulating concentration 
of IGF-I was significantly associated with the subsequent risk of developing 
prostate cancer. Those men whose circulating IGF-I concentration was in the 
highest fifth of the population had a 38% higher risk of developing prostate 
cancer (p<0.001) compared to those men whose IGF-I levels were in the lowest 
fifth [38].  This collaboration was subsequently updated with now 17 
prospective studies including 10,554 cases and 13,618 controls with the same 
association with IGF-I confirmed and now indicating a 29% increased risk of 
developing prostate cancer for men with IGF-I levels in the top quintile [39]. A 
conventional meta-analysis of 42 studies, including 7,481 cases, found a 
significant increased risk of prostate cancer with a 21% increase in risk for every 
standard deviation (SD) increase in IGF-I concentration across the population 
[40].  
The general high prevalence of occult prostate cancer in contrast to the 
geographical differences in prevalence of clinical disease and the changes in 
incidence of clinical disease in migrants between different regions of the world 
suggests that lifestyle and nutrition have a much greater effect on progression to 
clinical disease than on initiation. As described above, the circulating 
concentration IGF-I is a marker of nutritional/metabolic status and therefore the 
conventional epidemiology would predict that there would be a greater effect of 
IGF-I on progression to clinical disease than on initiation. There is some support 
for this: a study based on PSA-screening of a large population of 110,000 men 
identified 2,686 men with biopsy-confirmed asymptomatic prostate cancer 
found no association between the risk of these cancers and IGF-I. The odds-ratio 
(OR) per SD increase in IGF-I was 0.99 (confidence intervals (CI) 0.93-1.04) [41]. 
Furthermore, in an updated meta-analysis of population studies that were 
stratified according to whether the prostate cancers were detected by PSA-
screening or detected by traditional clinical presentation; distinctions were then 
found between associations with circulating IGF-I according to the method of 
detection. In studies based on clinically detected prostate cancers a significant 
association with IGF-I was still found; however no significant association was 
found in studies based on screen-detected prostate cancers, the vast majority of 
which would have been occult cancers  [41].   
Indirect evidence for a role of IGF-I in prostate cancer has come from studies of 
associations with physiological and pathological conditions in which IGF-I is 
implicated. The GH/IGF-I axis plays a major role in childhood growth and the 
attainment of adult height and in a systematic review of 22 population studies 
most found that greater height increased the risk of prostate cancer by between 
20-40% when comparing men in the tallest category with those in the shortest 
category [42]. In a recent large international consortium study with 6,207 
prostate cancer cases and 6,016 controls men who were taller than 180cm had a 
22% higher risk of prostate cancer (OR 1.22, CI 1-01-1.48) in comparison to men 
who were shorter than 173cm [43]. This study also analysed genetic variants in 
the growth pathways (including single nucleotide polymorphisms (SNPs) in the 
GH and IGF-I genes) and found the aggregate score of the genetic variants was 
associated with an increased risk of overall prostate cancer (OR 1.13) and high-
grade prostate cancer (OR 1.15) [43]. Acromegaly results from pituitary tumours 
secreting high levels of GH and as a consequence circulating IGF-I levels are 
extremely high. In a recent study using national hospital episode and mortality 
data 2,495 men with acromegaly were identified and compared with a reference 
cohort of 4.3 million men with 30,000 prostate cancer deaths. For men with 
acromegaly the risk of a diagnosis of prostate cancer was increased by 33% (CI 
1.09-1.63) and the risk for prostate cancer death was increased by 44% (CI 0.92-
2.26) [44]. This observation may be confounded due to reports that serum IGF-I 
levels are associated with lower urinary tract symptoms (LUTS) in elderly men 
[45] and are increased in men with benign prostatic hyperplasia (BPH) [46]. In 
addition, acromegaly, a pituitary tumor resulting in increased serum IGF-I, in 
men is associated with prostate enlargement and with increased LUTS [47,48]. 
Prostate enlargement and LUTS may both increase the risk of investigation and 
detection of prostate cancer which could confound associations with 
acromegaly; however, this could also reflect a pathway with IGF-I increasing 
prostate epithelial proliferation and survival and increasing prostate size and the 
risk of cancer. 
 
Studies with clinical follow-up can give the clearest evidence in relation to 
clinically important life-threatening prostate cancer.  In a study of 909 men with 
PSA-detected clinically localized prostate cancer who were undergoing active 
monitoring, after a mean of 4 years follow-up there was some evidence of an 
association between their initial serum IGF-I level and their risk of signs of 
disease progression as assessed by a rapid PSA doubling time. For every SD 
increase in serum IGF-I their odds ratio risk of developing a rapid PSA doubling 
time was 1.34 (CI 0.98-1.81) [49]. In a study of 396 men with clinically advanced 
prostate cancer followed-up for a mean of 3.7 years with 66 cancer-specific 
deaths there was a significant association between serum IGF-I and mortality 
after controlling for the level of IGFBP-3 with a hazard ratio of 1.59 (CI 1.11-
2.28) per SD change in IGF-I. However, in a larger prospective study of 2,424 
men with a mean follow-up of 8.9 years with 313 prostate cancer specific deaths 
no association was found between prediagnosis levels of IGF-I and mortality 
[50]. An association between serum IGF-I and pathological Gleason score was 
examined in a study of 793 men who underwent radical prostatectomy with 272 
control men with negative biopsies. An inverse association was found with low 
IGF-I levels associated with high Gleason score and an increase in Gleason score 
between biopsy and surgical specimen was most frequent in men with low 
serum IGF-I [51]. It was hypothesized that high-grade prostate cancers may 
develop independent of IGF-I. 
Observational studies are prone to many potential confounders such as reverse 
causality; cancer is known to affect metabolic and endocrine status. This could 
explain associations between IGF-I and prostate cancer. In order to overcome 
such issues many studies have examined associations between genetic variants 
in the IGF-I pathway and prostate cancer. Gene alleles randomly assort at gamete 
formation and segregate randomly at conception to generate a genotype that 
remains throughout life. Associations between genotypes and prostate cancer 
cannot be explained by reverse causality and are generally not confounded by 
behavioral or environmental factors.  In addition, a genotype may be more 
reflective of a lifetime exposure than a single measure of a serum or tissue 
sample. Initially studies examined associations with SNPs in the IGF-I and related 
genes. The increasing availability of data from genome-wide association scores 
then enabled the calculation of genetic scores from multiple gene variants that 
best predict exposures such as the circulating level of IGF-I that were then used 
in Mendelian Randomisation studies. Of the studies examining single genetic 
variants most observed an association between genetic variance in IGF-I and the 
risk of prostate cancer although most were small studies lacking statistical 
power [52-57]. Of two larger studies, a consortium study with 6,012 cases of 
prostate cancer and 6,641 controls identified a SNP that was not associated with 
blood IGF-I levels but was associated with prostate cancer risk [56]. Another 
consortium study with 2,664 cases and 2,919 controls however found no 
association between the genetic variance that was related to blood IGF-I levels 
and prostate cancer risk [58]. A comprehensive Mendelian randomization study 
using genetic variants as instruments for circulating levels of IGFs and IGFBP-3 
examined associations with prostate cancer risk using consortia data with 
22,992 cases and 22,936 controls. The main finding was that there was 
considerable pleiotropy for the genetic instruments with the strongest 
instruments being SNPs in the IGFBP-1/IGFBP-3 region [59]. A meta-analysis of 
18 individual studies also indicated that genetic variance in IGFBP-3 was 
significantly associated with an increased risk of prostate cancer [60]. The 
association with IGFBP-3 is entirely consistent with our current understanding 
of the physiology, as described above, with IGFBP-3 having a dominant effect on 
the circulating concentrations of both IGF-I and IGF-II. Significant associations 
were found between the genetic instruments and prostate cancer, particularly 
high-grade cancers; however, due to the pleiotropy, the evidence could only 
implicate the IGF-pathway rather than any specific component [59]. Consistent 
with the concept that the IGF-pathway may be particularly important for 
progression, many studies have found associations between genetic variance and 
clinical outcomes. In a study of 320 men post radical prostatectomy, IGF-I 
genotypes were associated with a 1.49- to 2.22-fold higher risk of advanced-
stage prostate cancer and a genetic interaction between SNPs in IGF-I/IGF-IR 
was significantly associated with evidence of biochemical recurrence [61]. A 
study of 215 men with prostate cancer and bone metastasis polymorphisms in 
the IGF-I gene were associated with cancer-specific survival [62]. A large 
consortium study of 5,887 men with prostate cancer and 704 cancer-specific 
deaths found that genetic variance in the IGF-pathway were associated with 
mortality [50]. Interestingly the two SNPs with the strongest associations with 
mortality were in the IGF-II antisense gene and the somatostatin receptor 2 [50]. 
 
3. Evidence from Preclinical Studies. 
There is overwhelmingly convincing preclinical evidence for a potential role for 
IGFs in prostate cancer from studies of prostate cells in vitro and a variety of 
animal models in vivo. At the cellular level IGFs have been consistently shown to 
stimulate the growth, metabolism, survival, migration and invasion of prostate 
cancer cells as we [63] and others [64] have reviewed earlier. The IGF-pathway 
appears to play an important role in many of the critical stages of cancer 
progression including supporting cancer stem cells, endothelial-to-mesenchymal  
transition(EMT), angiogenesis, immune escape, invasion and metastasis [65,66]. 
In addition, IGF-I has been reported to drive EMT of prostate cancer cells, a 
cellular de-differentiation that is key to enhanced migration, invasion and 
metastasis [67]. Furthermore, IGF-I stabilizes important integrin receptors on 
prostate cells that determine cell attachment and changes in cell attachment are 
critical to cancer progression [68]. Genetic over-expression or silencing of either 
the IGF-IR or the IR in prostate cancer cells reduces growth, migration, 
angiogenesis and tumorigenesis in both cell lines and in mouse models [69,70]. 
In addition to its conventional role in cell-surface signaling, the IGF-IR has also 
been reported to localize within the nucleus of prostate cancer cells where it was 
reported to interact directly with chromatin to enhance the expression of a 
number of genes associated with prostate cancer progression [71].  
A mouse model that better reflects human disease in contrast to xenograft 
models is the autochthonous Transgenic Adenocarcinoma of Mouse Prostate 
(TRAMP) model in which SV40 early gene expression is targeted to the prostatic 
epithelium, with expression starting at sexual maturity. The TRAMP mice 
initially develop prostatic intraepithelial neoplasia but ultimately develop 
adenocarcinomas that metastasise to other sites, primarily lymph nodes and 
lungs. Following androgen ablation 20-35% of TRAMP mice remain cancer free 
but 65-80% develop androgen-independent disease [72]. A comprehensive 
characterisation of the IGF-system in TRAMP mice revealed that prostatic IGF-I 
expression was increased in primary disease; in contrast expression of IGF-IR 
and IGF-IIR were not altered in primary disease but were dramatically reduced 
in metastatic lesions and in androgen-independent disease [72]. When TRAMP 
mice are fed a high fat diet there was an increase in incidence of tumors and 
increased mortality and this was associated with an increase in serum IGF-I and 
staining for the IGF-IR in the prostate [73]. The human population studies 
implicated a role for circulating IGF-I in promoting prostate cancers. This 
potential role has been tested in mice by crossing mice that develop prostate 
adenocarcinomas due to transgenic expression of the oncogene C-Myc with mice 
that are transgenic for over-expression of IGF-I specifically in the liver, 
generating high circulating IGF-I levels. The high circulating IGF-I in the mice 
resulted in an increased incidence and invasiveness of prostate cancers; there 
was also evidence that there was cooperation between the high IGF-I and c-Myc 
to promote IGF-IR expression in the tumors [74]. 
The development of the prostate gland is dependent on androgens and a 
reciprocal synergistic interaction between the IGF-system and the androgen 
receptor has been demonstrated to operate in prostate cancer cells. The 
expression of the IGF-IR receptor is up-regulated by androgens [75] and 
reintroduction of functional, but not mutant, androgen receptors into prostate 
cancer cells lacking this receptor results in increased expression of the IGF-IR 
[76]. The IGF-IR can also activate the androgen receptor in prostate cancer cells 
independent of the occupation of the receptor by androgens [77,78]. This 
androgen-independent activation of the androgen receptor suggested a potential 
mechanism for the development of castration resistant prostate cancer and 
indeed inhibition of the IGF-IR did enhance the inhibitory effects of castration in 
a mouse model [79]. The involvement of the IGF-system in the development of 
androgen-independence has also been implicated by reports of increases in IGF-
I, the IGF-IR [80], IGFBP-2 [81] and IGFBP-5 [82]; all of which could promote 
progression in the absence of androgens. In multiple preclinical prostate cancer 
cell models, including a patient-derived castration-resistant xenograft (PDX) 
model, an IGF-neutralising antibody in combination with an androgen receptor 
signaling  inhibitor reduced the survival of prostate cancer cells more than either 
agent alone and the IGF-neutralising antibody inhibited the growth of the 
castration resistant PDX tumors in vivo [83]. Despite all of these preclinical 
indications, this however did not translate into any positive effect of combining 
IGF-IR blocking antibodies with androgen deprivation in a phase II clinical trial 
[84].  
A number of oncogenes and tumor suppressor genes activate or interact with the 
IGF-pathway [85,86]. For example the breast and ovarian cancer susceptibility 
gene-1 (BRCA1) was found to regulate the IGF-IR in prostate cancer cells, 
suppressing the expression of the IGF-IR in androgen receptor negative cells but 
up-regulating it in androgen receptor positive cells [87]. Also of particular 
importance to prostate cancer are the frequently observed fusions between the 
TMPRSS2 gene and the ERG gene which links an androgen driven promoter with 
an oncogenic transcription factor [88]. The TMPRSS2-ERG fusion appears to be 
an early event in prostate cancer progression and to be related to aggressive 
disease [89]. The ERG transcription factor was shown to bind directly to the IGF-
IR promoter and drive expression in prostate cells and the presence of the 
TMPRSS2-ERG fusion was shown to be associated with high IGF-IR expression in 
tumor samples from men [90,91].  
The potential importance of IGF-II for the development of prostate cancer was 
demonstrated by a study in mice in which mutations had been created in the IGF-
II/H19 imprinting control region that resulted in biallelic IGF-II expression [92]. 
Mice with biallelic expression of IGF-II showed an increase in the number and 
grade of multifocal prostatic intraepithelial neoplasia, a premalignant lesion, 
indicating that IGF-II promoted the rate of prostate cancer development. The 
factors that may induce loss of imprinting (LOI) resulting in biallelic expression 
of IGF-II are only starting to be unraveled but oxidative-stress has been reported 
to induce LOI in prostate cells in culture and in mouse models [93]. The plasticity 
of the epigenetic regulation of IGF-II/H19 was demonstrated by an increase in 
the expression of both IGF-II and H19 in the prostates of mice exposed to a 
methyl-deficient diet [94]. An additional mechanism of regulation of IGF-II was 
apparent with the report that the IGF-II antisense transcript can down-regulate 
the expression of IGF-II and act as a tumor suppressor in prostate cancer cells 
[95,96]. Additional effects of IGF-II have been suggested with the report that 
prostate cancer resistance to chemotherapy was mediated by IGF-II and that IGF-
II can promote de novo steroidogenesis within prostate cancer cells [97].  
Other products of the IGF-II/H19-locus have also been implicated in the 
development of prostate cancer. The long non-coding RNA H19 has been 
reported to down-regulate integrin receptors on prostate cancer cells and 
promote their mobility and invasion [98] and to promote ‘stem-like’ properties 
in prostate cells [99]. In addition, miR-675, derived from H19, has been reported 
to suppress prostate cancer metastasis by repressing the expression of TGF- 
induced protein [100].  The other micro-RNA derived from within IGF-II, miR-
483, has also been reported to promote the proliferation and invasion of 
prostate cancer cells [101]. 
Prostate cancer only becomes a lethal disease when it spreads beyond the 
confines of the prostate gland and one of the most common sites for metastasis is 
the bone with the incidence reported between 18-29% of men with prostate 
cancer in the USA [102]. The IGF-system appears to be critical for the 
development, growth and maintenance of normal bone [103,104]. Normal bones 
are maintained by constant dynamic cell growth and turnover in a local 
environment that is rich in growth factors. In this environment IGF-I is produced 
by osteoblasts, dendrocytes, osteoclasts and osteocytes and is stored with 
IGFBPs in the bone matrix [103]. This provides an ideal environment to attract 
tumor cells and for them to then proliferate [105,106]. The importance of IGFs to 
the metastasis of prostate cancer to bone was indicated by the ability of a 
neutralizing antibody to IGF-I and IGF-II to inhibit the growth of prostate cancer 
cells in human bone that had been implanted into severe compromised 
immunodeficient mice [107]. As IGF-II is by far the most abundant IGF present in 
bone a neutralizing antibody specific for IGF-II was shown to have a similar 
effect in the same model [108]. That the IGF-IR was mediating these effects was 
shown by the use of an IGF-IR inhibitor that potentiated the effects of 
simvostatin (a mevalonate pathway inhibitor) in inhibiting prostate cancer cells 
grown in co-cultures with mouse calvarial bone cells in vitro [109] and in a rat 
model of prostate cancer cells growing in bone [110]. 
The accumulation of evidence indicating an important role for the IGF-system in 
prostate cancer led to many preclinical studies investigating the effects of 
interventions targeting this system and these studies generally indicated a 
beneficial effect. With the IGF pathway having been implicated in a wide range of 
cancers a number of different strategies have been proposed to target the 
system. These include using antisense oligonucleotides or short interfering RNA 
to down-regulate the expression of IGF-I or the IGF-IR, dominant negative 
receptors, antibodies or small molecule tyrosine kinase inhibitors (TKIs) that 
block the IGF-IR. Several strategies have also been proposed that depend on 
sequestering the IGF ligands including antibodies that bind and neutralize the 
IGFs, both IGF-I and IGF-II, IGF ligand traps, recombinant IGFBPs and protease 
inhibitors that prevent the release of IGFs from IGFBPs [111]. Of these only the 
IGF-IR antibodies, IGF-IR TKIs and IGF neutralizing antibodies have been 
extensively developed for clinical application and these have been evaluated in 
preclinical models for prostate cancer. Antibodies blocking the IGF-IR have been 
reported to inhibit prostate cancer growth in cell lines and in mice, generally 
using xenograft models and either alone or in combination with docetaxel or 
androgen deprivation [79,90,112-116]. Additional encouraging results were also 
reported for IGF-IR TKIs in similar models [117-119] and in a rat model of bone 
metastasis [110]. 
 
4. Evidence from Clinical Studies.  
Clinical evidence of the involvement of the IGF system in prostate cancer comes 
from many studies documenting derangements to the system in samples from 
men with prostate cancer and more recently from clinical trials of agents 
targeting the IGF-pathway.  
The importance of IGF-I for the growth of the prostate gland is indicated by the 
association between IGF-I and BPH in normal men [46] and the increased 
prevalence of BPH in men with acromegaly [47,48]. The IGF system is perturbed 
in the prostate in men with BPH with increased expression of IGF-I, IGF-II and 
the IR [120]. The population studies, described above, indicate that high 
circulating IGF-I levels predispose to an increased risk of prostate cancer. A 
recent study analysed IGF-I concentrations in blood samples taken immediately 
before radical prostatectomy from 793 men and from 272 men who had negative 
prostate biopsies. Serum IGF-I levels were higher in the men with cancer, 
consistent with the prospective epidemiology, however they also found that in 
the men with cancer serum IGF-I concentrations decreased with increasing 
Gleason score of the cancers [51]. An increased grading of the Gleason score 
between the original biopsy and the surgical prostatectomy sample was also 
associated with a low serum IGF-I and the authors suggested that this may imply 
that the high grade disease may develop independent of serum IGF-I [51], 
although reverse causality cannot be exclude with disease progression resulting 
in lower serum IGF-I. 
Consistent with the animal models, clinical studies have also reported loss of 
imprinting of the IGF-II locus. The loss of imprinting has also been reported to 
extend into adjacent normal prostate tissue and not simply be confined to tumor 
tissue [121]. The LOI of IGF-II in normal prostate tissue was reported to increase 
with age in both mice and humans and this was more extensive in men with 
prostate cancer [122]. These findings could imply either that an epigenetic defect 
in the tumor is transmitted in a ‘field effect’ to the surrounding normal tissue or, 
more likely, that a more widespread epigenetic defect predisposes the prostate 
to the development of a cancer as is suggested by the increase in cancer in mice 
with an engineered loss of IGF-II imprinting [92]. Consistent with these reports 
an early study reported increased expression of IGF-II mRNA, but not protein in 
prostate cancer tissue compared to that from men with BPH [123]. The 
significance of IGF-II imprinting has however been questioned by recent reports 
that IGF-II expression and protein levels are actually decreased in human 
prostate tumors compared to adjacent non-neoplastic prostate [124] or 
compared to tissue from men with benign prostate hyperplasia [125]. In both 
studies the expression of IGF-II was not related to the IGF-II imprinting status 
but was related to promoter hypermethylation [124,125]. The discordance 
between imprinting status and IGF-II expression or levels has also been reported 
in other tissues and in a study comparing IGF-II imprinting status and serum 
IGF-II protein levels in white blood cells from men with prostate cancer and 
control men [126]. 
 
There have also been several reports of perturbations to other components of 
the IGF-II/H19 loci. Expression of H19 has been reported to be decreased in 
human prostate cancers [127]. In a screen of cell-free microRNA that could be 
detected in urine samples, the one microRNA found to be abnormal in men with 
prostate cancer was the microRNA embedded within the IGF-II gene, miR-483 
[128]. In a screen of microRNA isolated from lymphoblastoid cell lines derived 
from men in a study of families with a high risk of prostate cancer, miR-483 was 
one of 5 microRNAs associated with risk of cancer and a SNP associated with 
miR-483 was also associated with risk [129]. These reports indicate that further 
studies of miR-483 are warranted.  The levels of the IGF-II chaperone GRP94 
were suppressed in a tissue microarray study of men with prostate cancer and in 
circulating tumor cells derived from prostate cancer patients [130]. The IGF-II 
mRNA binding protein, IMP3, has been reported to be over-expressed in prostate 
cancer tissue and to correlate with Gleason score [131-133] and to be associated 
with extracapsular extension, seminal vesicle invasion, lymphovascular invasion 
and lower PSA recurrence-free survival [132]. Furthermore, IMP3 measured in 
serum samples was raised in men with prostate tumors compared to BPH, 
particularly those with metastatic disease, and to be associated with poor 
cancer-specific survival [133]. These reports are interesting, particularly those 
for IMP3 but it should be remembered that IMP3 and GRP94 are not specific 
exclusively for IGF-II and hence these findings may not directly implicate the 
IGF-system. 
 
The other component of the IGF-system that has been extensively investigated in 
human prostate cancers is the IGF-IR with conflicting findings.  The conflicting 
findings can, at least partially be attributed to problems with specificity of 
antibodies used for immunohistochemistry. An early report indicated that IGF-IR 
mRNA and protein were decreased in prostate tumors compared to benign 
epithelium [123]. However more recent studies have generally found the IGF-IR 
to be increased in prostate cancer. A study that included a rigorous evaluation of 
different antibodies found that staining for the IGF-IR was increased particularly 
in men showing signs of disease progression [134]. In a further study from the 
same group high IGF-IR was associated with shorter recurrence-free survival 
[135] and that whereas the IGF-IR was localised to cell membranes in benign 
epithelium it was more prominently localised to nuclear/cytoplasmic regions in 
malignant epithelium [71]. In a study of tissue microarray from radical 
prostatectomy samples increased IGF-IR and IR were also found and either high 
IR or low PTEN were associated with increased risk of biochemical recurrence 
and the worst prognosis was when both the IR was high and PTEN was low [35].  
In a large study of tissue from 805 radical prostatectomies increased IGF-IR or 
reduced PTEN were associated with worse prognosis [34]. In another large study 
of tissue from 769 men with advanced prostate cancer, the IGF-IR was increased 
in 29% and the IR increased in 10% of men and tumours with increased IGF-IR 
or IR showed increased cell proliferation and reduced apoptosis. In a follow-up, 
IGF-IR expression showed a borderline association with increased risk of lethal 
disease [136]. In contrast a study of samples from 270 men with more than 5 
years follow-up reported that in men who were negative for the TMPRSS2-ERG 
gene fusion, high IGF-IR was associated with prolonged biochemical progression 
free survival [137]. 
 
With preclinical, clinical and population evidence for the involvement of the IGF 
system in prostate cancer, the pharmaceutical industry then proceeded with 
clinical trials administering agents designed to block the IGF-pathway. As 
described above many different strategies have been proposed and evaluated to 
varying extents. Technical and safety issues have limited the development of 
most of these strategies and only IGF-IR blocking antibodies , TKIs and IGF-
neutralising antibodies have been evaluated clinically in men with prostate 
cancer. The most studied clinically have been blocking antibodies against the 
IGF-IR. These have been evaluated in men pretreated with docetaxel [138] or in 
combination with docetaxel [139,140] or with androgen deprivation therapy 
[84,141] and as a single therapy preoperatively in men with localized disease 
[142]. There have also been more limited clinical trials with IGF-IR TKI and 
neutralizing antibodies [111,143]. 
 
Although most agents have generally been well tolerated; they can result in 
hyperinsulinemia and dose-limiting hyperglycemia, especially agents that also 
block the IR.  In a trial in men with advanced prostate cancer, the IGF-IR-blocking 
antibody in combination with docetaxel resulted in more reported treatment-
related severe adverse events than in the docetaxel-alone control arm [140]. 
More than expected adverse events were also observed in the arm of a trial in 
which an IGF-IR-blocking antibody was used in combination with an mTOR 
inhibitor compared to the latter alone [144]. 
 
As with all the clinical trials of agents targeting the IGF-pathway in all other 
types of cancer, the pharmaceutical industry considered that these trials 
demonstrated limited objective responses, and in some combinations increased 
treatment related adverse effects. This resulted in most, bar a few trials, being 
terminated. In some of the trials clear evidence of antitumor activity was 
observed in particular patients; this was most evident in trials in patients with 
Ewing Sarcoma, but even in that case only around 10% of patients showed a 
response [111].  There was no clear evidence for why particular tumors or 
particular patients showed signs of clinical response. With such a relatively small 
proportion responding and no biomarker available to predict potential 
responders the major pharmaceutical companies considered these were not 
sufficient to justify continuing trials targeting the IGF-pathway for any type of 
cancer.  
 
Many different reasons have been proposed for the failure of agents targeting the 
IGF-system in clinical trials, despite the strong indications from preclinical 
evidence [111,143,145-147]. The actual reasons for the failure of these trials 
probably includes a combination of the suggested problems. One of the major 
issues is that all of these trials have, to date, been conducted in unselected 
patients and no other targeted cancer therapy has yet been found to be effective 
in unselected patients. The inclusion of many patients who do not respond for a 
variety of reasons, including some described below, dilutes any response that 
might have been observed in a subset of men. The reason that the trials were 
conducted in unselected men was due to a lack of convincing evidence for any 
potential predictive biomarker of response. Although there have been several 
suggestions, including levels of IGFs and their receptors; to date, there is not 
robust evidence for a biomarker that would predict which men would respond 
best to targeting the IGF-system. There are several reasons why some might not 
respond. The downstream signaling pathways activated by IGFs, especially the 
PI3K/PTEN pathway are commonly perturbed in prostate cancers by genetic, 
epigenetic and other alterations. If the downstream pathways are constitutively 
activated, then the cancer cells may be independent of interventions targeting 
upstream receptors. Another issue with trial design is that most have to be 
conducted in men with advanced disease who have failed conventional 
therapies. It is now clear that in patients with advanced cancers considerable 
intra-tumor heterogeneity has developed. Therefore, even if the major clone 
initially responds to blockade of the IGF-IR, the presence of minor clones with 
autonomous activation of the PI3K pathway could result in ultimate treatment 
failure as these clones will continue to grow and eventually take over. Similarly, 
compensatory signaling activation by other receptor tyrosine kinases, for 
example EGFR/HER2, that activate the same downstream intracellular signaling 
could render cells independent of the IGF-system. In addition, blocking the IGF-
IR can cause cell cycle arrest that could then limit the efficacy of specific 
cytotoxic drugs that act at different stages in the cell cycle; this could explain lack 
of response in trials of combination therapy. The IGF/insulin systems are 
endocrine pathways subject to feedback inhibition and blockade of the IGF-IR 
results in increased circulating IGF-I and insulin levels that could limit efficacy 
and in the case of short-acting TKIs may result in rebound activation of the 
pathway. The epidemiology, especially the autopsy findings, suggest that 
indolent prostate cancer is almost ubiquitous in elderly men and the evidence 
suggests that lifestyle and the IGF-system may be important in the initial 
progression from indolent disease to clinically relevant disease[16,147]. As 
already stated, most trials were initially in men with advanced disease where the 
cancer may already have acquired independence from stimulation by the IGF-
system. Interestingly one of the trials in prostate cancer with the most promising 
results was using an IGF-IR blocking antibody in men with localized disease 
prior to prostatectomy [142].  It has to be recognized, however that conducting 
large-scale clinical trials in men with early disease with objective clinical 
endpoints would be very challenging as relatively few of these men show disease 
progression in the timeframe of normal trials.  
 
These many reasons for lack of response are not mutually exclusive and in view 
of the recognized considerable intra-tumoral heterogeneity in prostate cancers it 
is likely that in any one man, many of these reasons combine to limit clinical 
response.  The lack of predictive biomarkers and the problems of identifying 
objective clinical responses in men with early disease present difficult challenges 
that future research needs to address. 
 
5. Expert Opinion. 
Preclinical, clinical and population studies have provided compelling evidence 
that the IGF-system plays an important role in the development of prostate 
cancer. This led to many clinical trials of agents targeting the IGF system in men 
with prostate cancer. These trials have now been terminated due to a lack of 
convincing objective clinical response; a decision made by pharmaceutical 
companies based on the results of trials not just in prostate cancer but across a 
number of different cancers. These trials were, however, all in unselected 
patients.  Promising results were obtained for prostate cancer in men with 
localised disease, but trials are unlikely to be resumed unless a convincing 
predictive biomarker is identified. Research into identifying such a predictive 
biomarker will continue although all of the most obvious components of the IGF 
system, including the levels of IGFs and their receptors, have been evaluated 
without any providing convincing robust evidence.   
The evidence however suggests that the IGF system provides such a strong 
advantage to the development of epithelial cancers that clones with constitutive 
activation of the pathway are selected during the evolution of most cancers, for 
example by activation of PI3K or suppression of PTEN. These clones are then less 
dependent on upstream activation of the pathway and contribute to the lack of 
efficacy of strategies blocking receptor activation and this also helps to explain 
why upstream components are poor predictive biomarkers. There are multiple 
compensating mechanisms and it is increasingly recognised that cell-signalling 
pathways are really intersecting networks. This means that it is also unlikely that 
a single downstream component will provide a robust predictive biomarker. In 
the future a more comprehensive understanding of signalling network activation 
may provide more predictive power but this is not on the immediate horizon. 
The most critical general question in prostate cancer is how to differentiate the 
indolent cancers that are virtually ubiquitous in elderly men (and do not need 
treatment) from the aggressive cancers that can shorten their lives (and do need 
treatment). In addition, even though more conservative approaches to 
population screening are being adopted, there will be increasingly large 
populations of worried elderly men living with the knowledge that they harbour 
a prostate cancer. Initial studies investigating the IGF-system as a marker for 
differentiating the aggressive cancers that need intervention from the indolent 
cancers have not been promising. The role of epigenetic reprogramming is 
however an interesting aspect that may well provide some exciting new insights 
over the coming years. Changes to the imprinting of the IGF-II/H19 locus appear 
to be a common early occurrence in prostate cancer; although this does not 
appear to simply result in increased IGF-II activity as initially anticipated. The 
IGF-II/H19 locus is however a source of a large array of lnc-RNA, micro-RNA, 
antisense-RNA and potentially other translated peptides that appear to form a 
very complex integrated regulation system. Little is still known regarding many 
of these components and how they interact is only beginning to be understood.   
This will be an exciting new field for the future that could yield new targets for 
controlling prostate and other cancers.     
The other area in which research into the IGF-system may be fruitful is in 
relation to lifestyle changes as a means to control cancers and maintain them in 
an indolent state in the growing population of elderly men. It is increasingly clear 
that many epithelial cancers, including that of the prostate, are yet another 
adverse consequence of the lifestyle that has been widely adopted in developed 
societies, in addition to the obvious consequences such as obesity and type 2 
diabetes.  It is now recognised that rapidly turning-over epithelial surfaces, such 
as prostate epithelium, acquire huge numbers of potentially oncogenic mutations 
and epigenetic changes as men age. As a consequence most elderly men will 
develop multiple indolent neoplastic lesions in their prostate gland, as confirmed 
by population studies particularly the autopsy studies, mentioned above, that 
indicate indolent prostate cancer is virtually ubiquitous in older men. There are 
multiple safeguards that prevent these lesions from progressing, including 
apoptosis, hypoxia and immune-surveillance.  The local tissue environment 
heavily influences the balance between the oncogenic drives to survive, 
proliferate and invade and these inherent defensive safeguards. The IGF system 
evolved as a critical component of the tissue environment signalling that the 
metabolic status is appropriate for growth and development.   It is increasingly 
apparent that the IGF system also plays a similar role in many tumors and 
mediates many of the effects of nutrition and metabolic status on cancer 
progression.  Over the coming years the IGF-system will be a key focus in the 
search for the most effective lifestyle interventions to control these naturally 
occurring indolent neoplastic lesions and allow men to live long healthy lives 
with their prostate cancer. Increasing use of screening will identify more men 
with prostate cancer, the vast majority of these will not develop into a life-
threatening disease. The epidemics of obesity and diabetes will however 
increase the chances that these men may progress to clinical disease. There will 
therefore undoubtedly be increasing numbers of worried men and over the next 
years there will be a growth in trials of interventions to reduce the chance that 
these men develop clinical cancer. As most of these men will not suffer from their 
indolent prostate cancer any secondary preventative interventions will have to 
be devoid of adverse health effects. This will favour interventions such as diet, 
exercise and drugs with proven safety profiles such as those used to improve 
metabolic health, for example metformin. The challenge with such trials will be 
that so few of these men will show signs of disease progression over even the 
most ambitious timeframe of a trial, such as five years, that objective clinical 
responses will be difficult to monitor. The IGFs have a very robustly established 
relationship with prostate cancer progression and they will be used as an 
intermediate biomarker to indicate that the intervention has resulted in changes 
likely to affect the progression of the disease. There will be more studies 
characterising the nutritional changes that are most effective in modulating the 
IGF/insulin system that could reduce its effects on promoting cancer 
progression. As tumor heterogeneity is increasingly recognised as an 
impediment to many therapies and a leading cause of disease recurrence there 
will be increasing studies of factors that impact tumor heterogeneity. The 
IGF/insulin system and its downstream signalling pathways are prime factors 




• The IGF system plays an important role in prostate cancer development. 
Evidence, particularly from population studies, indicates that the most 
important effect may be early in the progression from indolent disease to 
clinical cancer. This helps explain the lack of objective clinical responses 
in trials largely performed in men with advanced disease. It also provides 
opportunities as increasing numbers of men are diagnosed with indolent 
disease by screening. 
• Clinical trials in men with prostate cancer of agents targeting the IGF-
system are unlikely to resume unless convincing predictive markers are 
identified that could enable the selection of men most likely to respond. 
• As IGFs are nutritionally dependent and they affect the progression of 
prostate cancer they provide an opportunity to monitor interventions 
aimed at reducing the risk for men with indolent disease. As most men 
will not suffer from their indolent prostate cancer any intervention will 
have to be safe from adverse effects. This favours nutritional/lifestyle 
interventions over pharmaceutical interventions. A better understanding 
of the nutritional determinants of IGFs will assist these studies. There are 
major differences in IGF-physiology between different animal species and 
these differences explain why IGF-levels are more responsive to 
nutritional changes in rodents compared to humans. These differences 
however limit the usefulness of animal models for such studies.   
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Fig 1. Overview of intracellular signaling of the IGF system. At the cellular level 
IGF-I, IGF-II and insulin ligands interact with a family of signaling tyrosine kinase 
receptors: the IGF-IR and the insulin receptor IR, which exists in two 
alternatively spliced isoforms (IRα and IRβ). The IRβ has high affinity to insulin 
whereas the IRα to IGF-II. Upon binding of the ligands to the receptors  signalling 
cascade is initiated. Conformational changes within the intracellular β-subunit 
result in autophosphorylation of insulin receptor substrates (IRS-1 to−4), Shc. 
This then results in activation of  PI3K/Akt/mTOR/S6K and 
Grb2/SOS/Ras/Raf/MEK/ERK pathways. Such cascade of intracellular reaction 
culminates in increased cell proliferation, tumorigenesis, self-renewal, 
homeostatis and metabolism The lipid kinase activity of PI3K, that recruits and 
activates Akt, is opposed by the lipid phosphatase PTEN (phosphatase and tensin 
homolog), a tumor suppressor gene, the expression of which is commonly 
suppressed in many cancers including prostate. 
 
